Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI's Expert Panel

The approval was given to Covaxin after an expert panel met earlier in the day to review Phase 3 trial data.

(File Photo/ Getty)

New Delhi: The result for Phase 3 clinical trial of Bharat Biotech’s Covaxin vaccine is out as the Subject Expert Committee (SEC) under India's drug regulator on Tuesday gave approval to efficacy data for the Coronavirus jab.

According to the data submitted by Bharat Biotech, Covaxin has shown the efficacy of 77.8 per cent from the trial conducted on 25,800 subjects across the country, news agency ANI quoted citing sources.

The approval was given to country's only indigenous Covid-19 vaccine after an expert panel met earlier in the day to review Covaxin's trial data.

As per the procedue, SEC will not send Covaxin's Phase 3 trial data to Drugs Controller General of India (DCGI) for review.

Meanwhile, a recent study indicates that Covaxin prevented the risk of infection in more than 95 per cent of healthcare workers in India. The study, conducted by Apollo Hospitals, showed that post-vaccination, infection occurred in 1,355 people or 4.28 per cent among the vaccinated healthcare workers, while 294 or 5.14 per cent of the partly vaccinated workers tested positive.

The survey covered 31,621 healthcare workers who had received either both doses or the first dose of only Covishield or Covaxin vaccines between January 16 and May 30.

Recently, Bharat Biotech has dispatched its Covid-19 vaccine Covaxin to nine states through the government of India and to 16 states through the respective state governments.

The states are Assam, Bihar, Chhattisgarh, Delhi, Haryana, Jharkhand, Karnataka, Madhya Pradesh, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Tripura, Uttarakhand and West Bengal.